GlassScriptPhysician profile
Richard A Fermelia
NPI 1851486831
$1,046.82
in general payments reported to CMS, 2019-2025
18 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $87.72 · 2021: $109 · 2022: $219 · 2023: $121 · 2024: $173 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $179.15 | 2019 | |
| Novo Nordisk INC | $154.64 | 2020-2024 | Wegovy |
| Boston Scientific Corporation | $143.13 | 2025 | Overstitch Nxt Endoscopic Suturing System |
| Otsuka America Pharmaceutical, INC. | $104.07 | 2020-2025 | Rexulti |
| Alkermes, INC. | $97.44 | 2021-2024 | Aristada, Vivitrol, Lybalvi |
| Janssen Pharmaceuticals, INC | $54.93 | 2022-2024 | Spravato |
| Abbvie INC. | $54.16 | 2021 | |
| Abbott Laboratories | $52.75 | 2022-2023 | Freestyle Libre 2 |
| Dexcom, INC. | $29.16 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $25.82 | 2022-2023 | Belsomra |
| Beta Bionics, INC. | $23.11 | 2024 | Ilet Bionic Pancreas |
| Heron Therapeutics, INC. | $22.92 | 2022 | |
| Dermira, INC. | $20.61 | 2020 | |
| Gilead Sciences, INC. | $20.15 | 2024 | |
| Orexo US, INC. | $18.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.40 | 2023 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $14.64 | 2024 | |
| Medtronic, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Fermelia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.